The next five years of pharma: Pricing, biosimilars, and specialty medicines
A report from the IQVIA Institute for Human Data Science identified areas to watch through 2023.
Biosimilars
Pfizer lawsuit could clear path for biosimilars
Biosimilars have only been in the market for three years, but they have struggled to compete with their branded equivalents.
Sandoz lines up potential third-to-market Humira copy
Although if approved, it’s not likely to launch in the U.S. for quite some time.
Five things for pharma marketers to know: Wednesday, January 10, 2018
Maker of Botox biosimilar Evolus files IPO; pharma execs expect major acquisitions in 2018; J&J and Bayer win Xarelto reversal verdict
Five things for pharma marketers to know: Wednesday, December 20, 2017
Tax bill could lead pharma to move overseas; global pharma sales increased 45% in nine years; FDA OKs first gene therapy for rare retinal disease
Five things for pharma marketers to know: Wednesday, November 22, 2017
WebMD reportedly lays off 10% of workforce; Roche blocks Herceptin biosimilar with patent suit; insurers cover Collegium’s Xtampza over Purdue’s OxyContin
Five things for pharma marketers to know: Wednesday, November 15, 2017
FDA approves AstraZeneca asthma drug; Senate tax reform bill would repeal Obamacare mandate; J&J drops Remicade biosimilar lawsuit
Why haven’t biosimilars gained ground in the U.S.?
Two years after the first biosimilar approval in the U.S., biosimilars have yet to match sales forecasts. What is their path forward?
Five things for pharma marketers to know: Wednesday, October 25, 2017
FDA develops resources about biosimilars for HCPs; Biogen negotiates royalties for experimental Alzheimer’s drug; GSK Q3 sales driven by HIV, respiratory drugs
Five things for pharma marketers to know: Monday, October 23, 2017
Biosimilars could save $54 billion in next decade; White House requests drug-pricing task force; FDA approves GSK shingle vaccine
